Michael Thomas Henderson Sells 10,000 Shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE - Get Free Report) CEO Michael Thomas Henderson sold 10,000 shares of the firm's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $30.15, for a total value of $301,500.00. Following the sale, the chief executive officer now directly owns 1,292,987 shares in the company, valued at approximately $38,983,558.05. This represents a 0.77 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Michael Thomas Henderson also recently made the following trade(s):

• On Wednesday, February 5th, Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $40.58, for a total transaction of $608,700.00.
• On Wednesday, January 8th, Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $48.85, for a total transaction of $732,750.00.

Apogee Therapeutics Trading Up 7.3 %

Shares of NASDAQ:APGE traded up $2.73 during trading on Tuesday, hitting $40.27. 988,378 shares of the company were exchanged, compared to its average volume of 494,960. Apogee Therapeutics, Inc. has a fifty-two week low of $29.10 and a fifty-two week high of $72.29. The stock has a market cap of $1.81 billion, a price-to-earnings ratio of -16.64 and a beta of 2.46. The firm has a fifty day moving average price of $38.68 and a two-hundred day moving average price of $46.77.

Remove Ads

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($1.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.25). As a group, research analysts predict that Apogee Therapeutics, Inc. will post -3.09 EPS for the current year.

Institutional Investors Weigh In On Apogee Therapeutics

Several hedge funds have recently bought and sold shares of the company. Point72 Asset Management L.P. raised its stake in Apogee Therapeutics by 162.7% in the third quarter. Point72 Asset Management L.P. now owns 707,268 shares of the company's stock valued at $41,545,000 after buying an additional 438,036 shares during the period. Geode Capital Management LLC increased its holdings in shares of Apogee Therapeutics by 11.2% during the 3rd quarter. Geode Capital Management LLC now owns 823,839 shares of the company's stock worth $48,401,000 after acquiring an additional 82,978 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Apogee Therapeutics by 17.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 280,428 shares of the company's stock valued at $16,472,000 after acquiring an additional 41,686 shares during the period. Vestal Point Capital LP acquired a new stake in Apogee Therapeutics during the 3rd quarter valued at $8,018,000. Finally, Victory Capital Management Inc. boosted its position in Apogee Therapeutics by 121.6% during the third quarter. Victory Capital Management Inc. now owns 346,358 shares of the company's stock worth $20,345,000 after purchasing an additional 190,092 shares during the period. 79.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Wedbush restated an "outperform" rating and issued a $90.00 price target on shares of Apogee Therapeutics in a report on Tuesday. Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a research report on Monday, November 25th. They set a "buy" rating and a $89.00 price target for the company. Canaccord Genuity Group initiated coverage on shares of Apogee Therapeutics in a report on Monday, November 25th. They issued a "buy" rating and a $89.00 price objective on the stock. Finally, Guggenheim reissued a "buy" rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Apogee Therapeutics presently has an average rating of "Buy" and an average target price of $91.60.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.